ORKA · Oruka Therapeutics, Inc. · Insider Trading

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.21 to $79.72, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.70 to $77.57, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.61 to $76.42, inclusive.

The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.47 to $75.30, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.16 to $79.15, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.68 to $77.74, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.22 to $75.86, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.21 to $74.20, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.27 to $77.23, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.22 to $75.18, inclusive.

The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.56 to $81.53, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.61 to $82.50, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.55 to $80.54, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $82.91, inclusive.

The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive.

The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.87 to $92.78, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.05 to $95.75, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.02 to $94.98, inclusive.

The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.56 to $92.55, inclusive.

The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.62 to $93.54, inclusive.

The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.04 to $94.35, inclusive.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.52 to $91.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.98 to $94.05, inclusive.